本次公司获得法莫替丁注射液的《药品注册证书》，进一步丰富了公司的产品线，有助于提升公司产品 的市场竞争力。上述《药品注册证书》的取得预计不会对公司近期经营业绩产生重大影响。 智通财经APP讯，联环药业(600513.SH)发布公告，公司于近日收到国家药品监督管理局(简称"国家药监 局")核准签发的法莫替丁注射液《药品注册证书》。法莫替丁注射液是一种通过抑制胃酸分泌发挥治疗 作用的药物，属于组胺H2受体阻滞药。 ...

Core Viewpoint - The company has received the drug registration certificate for Famotidine injection from the National Medical Products Administration, which enhances its product line and market competitiveness [1] Summary by Relevant Sections - **Product Approval** - The company has obtained the drug registration certificate for Famotidine injection, a medication that works by inhibiting gastric acid secretion and belongs to the H2 receptor antagonist class [1] - **Impact on Product Line** - The approval of Famotidine injection enriches the company's product offerings, contributing to improved market competitiveness [1] - **Financial Impact** - The acquisition of the drug registration certificate is not expected to have a significant impact on the company's recent operating performance [1]

Group 1 - The first domestically developed pediatric influenza antiviral drug, Maduonosawei granules, has had its market application accepted, targeting the treatment of influenza A and B in children aged 2 to 11 without complications. This marks a significant milestone for the Chinese pharmaceutical industry [1] - The approval of this pediatric drug is expected to provide a new growth point for Xiansheng Pharmaceutical and enhance its competitiveness in the influenza drug market, while also showcasing the innovative drug development capabilities of Antikang Bio [1] Group 2 - Huasheng Technology announced plans to re-list the transfer of a 51% stake in its subsidiary, Tibet Kangyu Pharmaceutical Co., Ltd., with a listing price of 42.5 million yuan. The company has not yet found a suitable buyer after two rounds of bidding, indicating potential market valuation discrepancies [2] - The failure to attract qualified buyers may reflect concerns regarding the future development, competitive landscape, and financial status of Kangyu Pharmaceutical, making the outcome of the re-listing uncertain [2] Group 3 - Lianhuan Pharmaceutical's subsidiary, Xinxiang Changle Pharmaceutical Co., Ltd., has received domestic approval for its Amlodipine Besylate tablets, a commonly used medication for regulating vascular pressure, with annual sales expected to reach 1.216 billion yuan in 2024 [3] - This approval enhances the product line of the company and its subsidiaries, improving market competitiveness, although the market is already crowded with numerous participants [3] Group 4 - Medisi's wholly-owned subsidiary, Medisi Puya Pharmaceutical Technology (Shanghai) Co., Ltd., has been sued for 159 million yuan due to a technical service contract dispute, with the case already filed but not yet heard [4] - The uncertainty surrounding this lawsuit may increase operational risks for the company and could lead to investor concerns regarding its future development [4] Group 5 - Shanghai Laishi announced that several executives, including the vice chairman and general manager, plan to increase their shareholdings in the company, with a total investment of no less than 6 million yuan sourced from personal funds [5] - Executive share purchases are generally viewed as a positive signal in the capital market, potentially attracting more investor interest and driving up stock prices, although the effectiveness of this plan will depend on market conditions and the company's actual performance [5]

Core Viewpoint - Jiangsu Lianhuan Pharmaceutical Co., Ltd. announced that its subsidiary, Xinxiang Changle Pharmaceutical Co., Ltd., has received the Drug Registration Certificate for Amlodipine Besylate Tablets from the National Medical Products Administration, which is expected to enhance the company's product line and market competitiveness [1][2]. Drug Registration Details - The drug registered is Amlodipine Besylate Tablets, available in dosages of 5mg and 10mg, classified as a chemical drug of category 4, and is a prescription medication [1][2]. - The sales revenue for Amlodipine Besylate Tablets in hospitals across China reached 1.216 billion yuan in 2024 [2]. R&D Investment and Production - As of the announcement date, the R&D investment for Amlodipine Besylate Tablets by Changle Pharmaceutical is approximately 3.83 million yuan (unaudited) [2]. - Changle Pharmaceutical has obtained four production licenses for the drug as of the announcement date [2]. Impact on the Company - The acquisition of the Drug Registration Certificate is expected to enrich the product line of the company and its subsidiaries, thereby enhancing their market competitiveness [2]. - The impact on the company's recent operating performance is not expected to be significant [2].

Group 1: Company Announcements - Heng Rui Medicine has received the clinical trial approval notice for HRS-4729 injection, a self-developed peptide drug targeting GLP-1R, GIPR, and GCGR receptors, with no similar products approved in the market [1] - Hubei Yihua has successfully launched its 200,000 tons/year caustic soda project, aimed at upgrading its chlor-alkali chemical industry and enhancing market competitiveness [2] - Ji Min Health announced that its shareholder, Shuangge Group, plans to reduce its stake by up to 3%, equating to a maximum of 15.75 million shares [3] - China Shipbuilding intends to absorb and merge with China Shipbuilding Industry Corporation through a share exchange, with the latter's A-shares set to be delisted on September 5, 2025 [4] - Changfei Fiber reported that its shareholder, Changjiang Communication, plans to reduce its stake by up to 0.15%, totaling no more than 1.1 million shares [5] Group 2: Strategic Collaborations and Developments - Beijing Lier has signed a strategic cooperation agreement with SenseTime and Xiwang Technology to explore AI computing power collaboration and related applications [6] - Junsheng Electronics is collaborating with leading clients like Zhiyuan Robotics, having achieved bulk supply of customized main control boards and various sensors [7][8] - Guoxin Technology has successfully tested a new generation of high-performance chips for automotive electronic BLDC motor control, aimed at addressing the MCU chip shortage in the automotive sector [9] Group 3: Other Corporate Actions - Guoguang Chain's actual controller plans to reduce their stake by up to 2.99%, totaling a maximum of 12.506 million shares [10] - Zhonghuan Hailu has terminated its control change plan, with its stock set to resume trading on September 5, 2025 [11] - Various companies have reported significant project wins, including Ningbo Construction winning contracts worth 1.117 billion yuan [12]

Group 1 - The core point of the article is that Lianhuan Pharmaceutical (600513) announced the approval of a drug registration certificate for Amlodipine Besylate Tablets by the National Medical Products Administration [1] Group 2 - The approved drug is Amlodipine Besylate Tablets, which is a medication used to treat high blood pressure and other cardiovascular conditions [1]

Group 1 - The core point of the article is that Lianhuan Pharmaceutical has received approval from the National Medical Products Administration for its product "Amlodipine Besylate Tablets" through its subsidiary [1] - Lianhuan Pharmaceutical's revenue composition for the year 2024 is as follows: 59.36% from pharmaceutical distribution, 40.38% from pharmaceutical manufacturing, and 0.26% from other businesses [1] - As of the report date, Lianhuan Pharmaceutical has a market capitalization of 6 billion yuan [1]

证券代码：600513 证券简称：联环药业 公告编号：2025-068 江苏联环药业股份有限公司 关于控股子公司获得《药品注册证书》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江苏联环药业股份有限公司（以下简称"公司"）控股子公司新乡市常乐 制药有限责任公司（以下简称"常乐制药"）于近日收到国家药品监督管理局 （以下简称"国家药监局"）核准签发的《药品注册证书》，现将相关情况公 告如下： | 药品名称 | 苯磺酸氨氯地平片 | | | --- | --- | --- | | 剂型 | 片剂 | | | 规格 | 5mg（按 C₂₀H₂₅ClN₂O₅计） | 10mg（按 C₂₀H₂₅ClN₂O₅计） | | 申请事项 | 药品注册（境内生产） | | | 注册分类 | 化学药品 4 类 | | | 处方药/非处方药 | 处方药 | | | 受理号 | CYHS2401760 | CYHS2401762 | | 证书编号 | 2025S02644 | 2025S02645 | | 药品批准文号 | 国药准字 H202 ...

Core Viewpoint - The company has received approval from the National Medical Products Administration for its subsidiary's drug, Amlodipine Besylate Tablets, which is commonly used to regulate vascular pressure [1] Group 1 - The drug Amlodipine Besylate Tablets has been officially registered, indicating a significant milestone for the company [1] - The approval enhances the company's product portfolio in the cardiovascular medication sector [1] - Amlodipine Besylate Tablets are recognized as a standard treatment for managing blood pressure [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for the registration of Amlodipine Besylate Tablets, which is a commonly used medication for regulating vascular pressure [1] Group 1 - The approved product is Amlodipine Besylate Tablets with specifications of 5mg and 10mg [1] - The approval was granted to the company's subsidiary, Xinxiang Changle Pharmaceutical Co., Ltd. [1] - This medication is significant in the treatment of hypertension and related cardiovascular conditions [1]